- Home
- OCGN vs CTNM Comparison
OCGN vs CTNM Comparison
Compare OCGN & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCGN
- CTNM
- Stock Information
- Founded
- OCGN 2013
- CTNM 2009
- Country
- OCGN United States
- CTNM United States
- Employees
- OCGN N/A
- CTNM N/A
- Industry
- OCGN Biotechnology: Biological Products (No Diagnostic Substances)
- CTNM
- Sector
- OCGN Health Care
- CTNM
- Exchange
- OCGN Nasdaq
- CTNM Nasdaq
- Market Cap
- OCGN 321.7M
- CTNM 328.1M
- IPO Year
- OCGN N/A
- CTNM 2024
- Fundamental
- Price
- OCGN $1.41
- CTNM $10.44
- Analyst Decision
- OCGN Strong Buy
- CTNM Strong Buy
- Analyst Count
- OCGN 2
- CTNM 5
- Target Price
- OCGN $7.00
- CTNM $22.20
- AVG Volume (30 Days)
- OCGN 4.4M
- CTNM 97.8K
- Earning Date
- OCGN 11-05-2025
- CTNM 10-30-2025
- Dividend Yield
- OCGN N/A
- CTNM N/A
- EPS Growth
- OCGN N/A
- CTNM N/A
- EPS
- OCGN N/A
- CTNM N/A
- Revenue
- OCGN $5,370,000.00
- CTNM N/A
- Revenue This Year
- OCGN N/A
- CTNM N/A
- Revenue Next Year
- OCGN N/A
- CTNM N/A
- P/E Ratio
- OCGN N/A
- CTNM N/A
- Revenue Growth
- OCGN 14.26
- CTNM N/A
- 52 Week Low
- OCGN $0.52
- CTNM $3.35
- 52 Week High
- OCGN $1.90
- CTNM $20.24
- Technical
- Relative Strength Index (RSI)
- OCGN 41.42
- CTNM 43.29
- Support Level
- OCGN $1.47
- CTNM $10.16
- Resistance Level
- OCGN $1.62
- CTNM $11.30
- Average True Range (ATR)
- OCGN 0.09
- CTNM 0.69
- MACD
- OCGN -0.03
- CTNM -0.15
- Stochastic Oscillator
- OCGN 27.27
- CTNM 12.02
About OCGN Ocugen Inc.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
About CTNM Contineum Therapeutics Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.